Catherine M. Bonuccelli has officially filed Form 3, marking her role as a director at IRulya Therapeutics Inc. This filing is significant as it reflects her commitment to governance and transparency within the company. It also emphasizes her involvement in the biological products sector, which is crucial for the company's future direction.
Bonuccelli's filing was submitted on October 19, 2026, under the accession number 0002159407-26-000002. This filing is part of the ongoing regulatory requirements for directors and officers in publicly traded companies.
Background
IRulya Therapeutics Inc., identified by the CIK 0001662774, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company was previously known as Quince Therapeutics, Inc. and has undergone a name change effective August 1, 2022. The firm is incorporated in Delaware and has its business address at 101 College Street, Suite 210, New Haven, CT.
What the Filing Says
The filing indicates that Bonuccelli is a director at IRulya Therapeutics Inc. and that she has no securities owned as of the date of the report, which was October 8, 2026. The filing includes a Power of Attorney, allowing designated individuals to execute necessary forms on her behalf, ensuring compliance with SEC regulations.
Impact
This filing may affect the company’s governance structure and transparency practices. As a director, Bonuccelli's decisions and leadership style could significantly influence IRulya Therapeutics' strategic direction and operational effectiveness in the competitive biological products industry.
What's Next
The filing does not say what happens next.